Replies to post #63714 on CYduct Diagnostics Inc (CYDX)

[frazier101]

Because the Mammoview is a very specific medical procedure that has not yet been fully adopted by medical facilities within the US.

The predominant Mammoview customers in the US have been government organizations and a few universities, all in a research realm.
There has been some reporting of hospitals using it but I would suspect that it is related to these institutions.

Many of the articles on studies I have read states that the commonly used mammography screening has provided similar results in identifying breast cancer lesions as the Mammoview. However using the mammography has yielded a 25% misdiagnosis in properly identifying lesions where the Mammoview has not. For what ever reason many US medical facilities, so far, have mitigated this 25% deficiency and have not replaced their dated mammography screening machines with the Mammoview. Yet.

I do not see this as being the case in Canada and in Europe for two reason. 1, According to a Global Cancer report, there are far more new cancer diagnosis and misdiagnosis in Canada and The European Union than there are in the US annualy. 2, Canada and the EU have establish socialized medicine programs that are working hard to eliminate the growing breast cancer epidemic.

I believe that Canada and the EU will adopt the Mammoview as the standard breast cancer early detection system and over time the US will follow suite. Especially as the Mammoview continues to evolve and the mammography becomes more obsolete.

All in my opinion of course.

GLTA

[ajsollii]

This has been answered many many times. The two systems are fundamentally different. One focuses on big industry (including pharm)and making money, the other, a more socialized system focused on preventative medicine and innovation. SNDY will fit right in to this type of system. As their success generates more momentum in the EU, more and more US systems will show interest...and sales will be through the roof. Not to mention the other innovative products the company brings to the table. Medical device industry sales in the US are focused on the larger producers/suppliers...and as stated by numerous post...it's reluctant to change...no boat rocking. Not the same in the EU. Much more opportunity to establish a foot hold...even 1% would generate enough "value" to send this company to unreal success. The potential here is TREMENDOUS!! But no, it won’t happen overnight. Even from this point, it will take years to appreciate to the levels some were hoping for last year. But in 2-5 years, this could absolutely hit $1. So…I hold shares for the long term potential of this solid little company.

[Aqua]

Solos management realized part of the reason for the dismal sales in the US has to do with potential customers in the healthcare industry having strict standards, and demand more accountability from medical device instrumentation manufacturers in the form of internationally recognized certifications to avoid the threat of medical lawsuits of their own. This in part provided management the motive to pursue the CE Mark certification despite the risks involves to shareholders. Being close to the official announcement of the CE Mark, Solos would be well positioned to compete internationally, including here in the US and engage in establishing a niche for its MammoView product line. Cheers!

[Elcappy1]

We're in 2013! About to be in 2014! Those #'s are old! SNDY